Millennium Management’s NovoCure NVCR Stock Holding History

Millennium Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-10,800	Closed	-$185K	–	6360
2024 Q2	$185K	Buy	10,800 +600	+6%	+$10.6K	﹤0.01%	5168
2024 Q1	$159K	Sell	10,200 -9,200	-47%	-$135K	﹤0.01%	5454
2023 Q4	$290K	Buy	19,400 +8,700	+81%	+$116K	﹤0.01%	4976
2023 Q3	$173K	Buy	10,700 +2,800	+35%	+$80.7K	﹤0.01%	5177
2023 Q2	$328K	Buy	+7,900	New	+$491K	﹤0.01%	4824
2023 Q1	–	Sell	-140,900	Closed	-$10.3M	–	6702
2022 Q4	$10.3M	Buy	+140,900	New	+$10.6M	0.01%	2089
2021 Q2	–	Sell	-16,000	Closed	-$2.12M	–	6914
2021 Q1	$2.12M	Buy	+16,000	New	+$2.53M	﹤0.01%	3476

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Millennium Management's NVCR Position: Q1 2026 in Review

Millennium Management reduced its NovoCure (NVCR) stake by 86% in Q1 2026, selling an estimated $6.94M and leaving 91,215 shares worth $994K. The position accounts for ﹤0.01% of the portfolio, ranked #4395.

Millennium Management first reported a position in NVCR in Q4 2015 and has held it in 36 quarters since. The position peaked at $21.9M in Q4 2024. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Millennium Management held 91,215 shares of NovoCure worth $994K as of Q1 2026.
Millennium Management sold 555,451 NovoCure shares in Q1 2026, an estimated $6.94M.
NovoCure made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #4395 holding.
Millennium Management first reported a position in NovoCure in Q4 2015 and has held it in 36 quarters since.
Millennium Management's NovoCure position peaked at $21.9M in Q4 2024.
223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.